Skip to main content
Signal8

Petros Pharmaceuticals, Inc. (PTPI)

Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.

Sector: Pharmaceutical Preparations

Industry: Drug Manufacturers - Specialty & Generic

Petros Pharmaceuticals, Inc. logo

Petros Pharmaceuticals, Inc.

OTC:PTPIHealthcare
+3.00%$0.0031
Mkt Cap$131K
EV-
Float42.28M
O/S42.37M
VOL56K sh
$ Vol$163
RVOL0.39×
Inst Own-
SI0.2%
Net Cash/Sh-
Dilution
Petros Pharmaceuticals, Inc. logoOTC:PTPI$0.0031+3.00%
FormDescription
8-K
10-Q
3
OWNERSHIP DOCUMENT
8-K
4
OWNERSHIP DOCUMENT
4
OWNERSHIP DOCUMENT
4
OWNERSHIP DOCUMENT
4
OWNERSHIP DOCUMENT
8-K
10-Q
10-K
Annual Report
NT 10-K
SEC Filing
13G/A
Beneficial Ownership Report (Amended)
4
OWNERSHIP DOCUMENT
4
OWNERSHIP DOCUMENT
8-K
5.02
4
OWNERSHIP DOCUMENT
4
OWNERSHIP DOCUMENT
25-NSE
SEC Filing
10-Q
Quarterly Report
8-K
3.01
8-K
4.01,9.01
13G/A
Beneficial Ownership Report (Amended)
10-Q
Quarterly Report
8-K
7.01,9.01

1-25 of 257

…

Recent SEC filings with analysis

    Petros Pharmaceuticals, Inc. (PTPI) SEC Filings | Signal8